Presentation (CTI)

OBJECTIVES: Introduction: In recent years, the rising incidence of prostate carcinoma among younger and middle-aged populations, along with diagnoses at more advanced stages, has led various authors to report an increase in treatment-related costs.
Objective: To conduct a systematic review of the literature on cost-utility studies comparing therapy with ¹⁷⁷Lu-PSMA versus taxane-based treatments such as cabazitaxel and standard care in patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC)
METHODS: A literature search was conducted using MeSH, DeCS, and free-text terms in combination with Boolean operators across several databases (PUBMED, Embase, Cochrane, INAHTA, LILACS, OpenGrey, and Google Scholar). A total of 459 articles were initially identified. After removing duplicates and excluding those without full-text availability, 4 articles remained. These studies were assessed for methodological quality using the CHEERS (Consolidated Health Economic Evaluation Reporting Standards) checklist.
RESULTS: The literature review identified three full economic evaluations and one partial evaluation regarding the costs of ¹⁷⁷Lu-PSMA therapy in patients diagnosed with castration-resistant prostate cancer. These studies compared the therapy with standard care following disease progression and prior to initiating cabazitaxel treatment. In three of the four studies, ¹⁷⁷Lu-PSMA therapy was found to be more costly in countries such as Norway, Canada, and the Netherlands, but not in the United States
CONCLUSIONS: Notably, some of the full economic evaluations published in countries like Canada lacked essential data typically required in economic evaluations, thereby limiting the interpretability of their findings